ID
22507
Beskrivning
Study ID: 100273 Clinical Study ID: HS2100273 Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Herpes Genitalis Visit description: Study conclusion
Nyckelord
Versioner (1)
- 2017-06-06 2017-06-06 -
Uppladdad den
6 juni 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study conclusion
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study conclusion
Similar models
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study conclusion
C0011008 (UMLS CUI [1,2])
C2826674 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
C0392360 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])